WHO WE ARE The mission of NanoSmart® Pharmaceuticals is to positively impact patients with cancer and other diseases worldwide by improving the safety and efficacy of existing pharmaceutical products. To achieve this, NanoSmart has developed a patented drug delivery system that takes already-approved cancer drugs and makes them safer and more effective. We believe that commercially-available drugs can be reformulated into new, proprietary drug products using NanoSmart’s tumor-targeting platform. This will enable the development of superior treatments for the cancer market while mitigating many risks inherent to early-stage innovator companies.
OUR TUMOR-TARGETING TECHNOLOGY NanoSmart is developing a human-derived anti-nuclear antibody that targets areas of necrosis present in many different types of cancer tumors. Combining this tumor-targeting antibody with our drug delivery system allows us to rapidly and economically develop significantly enhanced versions of drugs that are already on the market.
This tumor-targeting antibody can be incorporated into many different drug delivery formulations, such as liposomes and lipid nanoparticles, creating the potential for a very broad therapeutic drug pipeline. The liposome or lipid nanoparticles protect normal healthy cells from the drugs’ harmful side-effects, enabling more of the drug to act on the tumor over longer periods of time; while NanoSmart’s targeting antibody acts by anchoring the drugs directly at the tumor site. Refomulating already-proven drugs into NanoSmart's drug-delivery platform holds the promise of safer, more effective drugs that can target many different types of tumors. Please visit our Technology | Pipeline page for more information.
NANOSMART'S OPPORTUNITY Our proprietary tumor-targeting technology enables the creation of a very broad drug development pipeline that utilizes many existing cancer drugs and allows us to pursue treatments for a wide variety of cancers. A focus on pediatric cancer indications initially allows us to advance our lead candidate products through the commercialization process both rapidly and economically. Market entry of our first products will pave the way for us to efficiently expand our pipeline to other cancers and disease indications, while dramatically increasing the value of our core intellectual property. We also expect it to drive opportunities for collaboration with other pharmaceutical companies.